Business
Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference
Accelerating IMPT-314 in large B-cell lymphoma; remain on track to initiate pivotal trial in the 3rd line+ setting in 2025 and expect to initiate a pivotal
About this update from Lyell Immunopharma, Inc.
[{"type":"text","content":"Accelerating IMPT-314 in large B-cell lymphoma; remain on track to initiate pivotal trial in the 3rd line+ setting in 2025 and expect to initiate a pivotal trial in the 2nd line by early 2026Presenting additional data from the ongoing Phase 1-2 trial in 3rd line+ setting and initial clinical data in 2nd line setting in mid-2025Discontinuing development of LYL119, a ROR1-targeting CAR T-cell product candidate for solid tumors, to focus resources on acceleration of pivotal trials of IMPT-314 and next-generation solid tumor CAR T cell programs in preclinical developmentExpected net cash use of $175 million - $185 million for 2025 extends cash runway further into 2027 through multiple value-creating clinical catalysts, including new pivotal programsLynn Seely, MD, President and Chief Executive Officer, to present at J.P. Morgan conference on January 15th at 9:00 a.m. PT SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced pipeline updates, including its plans to advance IMPT-314, a potentially best-in-class therapy for aggressive large B-cell lymphoma, into pivotal trials. IMPT-314 is an autologous dual-targeting CD19/CD20 chimeric antigen receptor (CAR) T-cell product candidate designed to increase complete response rates and prolong the duration of the responses as compared to the approved CD19‑targeted CAR therapies for the treatment of large B-cell lymphoma. “Based on the positive initial clinical data reported at ASH and the promising emerging clinical profile, we are accelerating the development of IMPT-314 as a potentially transformative product with differentiated benefit in overall and complete response rates as well as duration of response over first-generation CD19 CAR therapies in patients with aggressive large B-cell lymphoma,” said Lynn Seely, M.D., Lyell’s President and Chief Executive Officer. “Having presented an initial dataset that demonstrated an overall response rate of 94% and a complete response rate of 71% in patients treated in the 3rd-line+ setting, we are focusing our resources on advancing IMPT-314 for patients with large B-cell lymphoma in both the 2nd and 3rd line+ settings. To ensure a sustainable cost structure that delivers ...